A Phase 3 interventional study of Docetaxel and DOXIL in Breast Cancer, sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C.. Completed at 151 sites in 18 countries. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-04-21.
Sponsored by Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (part of Johnson & Johnson) · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 67 studies testing liposomal doxorubicin in Breast Neoplasms — 5 open to participants now, 9 under way, 2 of them phase 3. liposomal doxorubicin · Breast Neoplasms.
Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, this one has the largest enrollment of the 66 interventional ones that give a count, is one of 2 that started in 2004, is one of 10 in phase 3, and was the 5th registered.
14,837 studies on the registry are indexed under Breast Neoplasms; 3,322 are open to participants now.
Browse Breast Neoplasms studies →5 of the 67 studies testing liposomal doxorubicin in Breast Neoplasms are open now, in 3 countries. Recruiting first, the newest first:
Fudan University · Sites in China
Ages 18–70
SCRI Development Innovations, LLC · Sites in United States
Ages 18+
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University · Sites in China
Ages 18–70 · Women only
Shanghai Pudong Hospital · Sites in China
Ages 18–70 · Women only
National Taiwan University Hospital · Sites in Taiwan
Ages 20+ · Women only
By country, each count listing its studies:
liposomal doxorubicin: first FDA approval 1995 (DOXIL (LIPOSOMAL)), first EMA approval 1996. What it is approved for, and how studies give it, is on its page →
Of the 2,400 Breast Neoplasms studies recruiting now, 1,572 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 214 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
67 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 42 · Phase 3 10 · Phase 4 6
First in 2000; this study’s year is marked. 2 started in 2004.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 751 is above the median of 72 across 10,908 interventional studies indexed under Breast Neoplasms.
Median enrollment 57 across the 66 interventional studies. Of the 40 that completed or were terminated, 18 (45%) have results posted.
This tab as a report to print or save as PDF → With an account.
14 of 67 have an industry lead sponsor. The 10 most frequent:
This study is registered under Johnson & Johnson Pharmaceutical Research & Development, L.L.C., one of the names counted as Johnson & Johnson. Under that name alone:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. is the lead sponsor of 465 studies on the registry; none are open to participants now.
19 studies in Breast Neoplasms by Johnson & Johnson: 1 open now, 2 under way, none of them phase 3. Of 16 finished, 6 (38%) have results posted.
Among the 19 studies in Breast Neoplasms by Johnson & Johnson, this one is the 3rd largest by enrollment of the 18 interventional ones that give a count, is one of 2 that started in 2004, is one of 7 in phase 3, and was the 4th registered.
Johnson & Johnson’s Breast Neoplasms studies by the year they started, since 1995.
2 of the studies testing liposomal doxorubicin in Breast Neoplasms that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03971409Laura Huppert, MD, BAAvelumab With Binimetinib, Sacituzumab Govitecan, or Liposomal Doxorubicin in Treating Stage IV or Unresectable, Recurrent Triple Negative Breast Cancer | 2027-01-31 |
| NCT05748834SCRI Development Innovations, LLCStudy of Tucatinib and Doxil in Participants With Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Metastatic Breast Cancer | 2027-11 |
Add all 2 to your calendar (.ics) → With an account.
Among the 67 studies testing liposomal doxorubicin in Breast Neoplasms, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Johnson & Johnson’s 19 in Breast Neoplasms:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of the study is to evaluate whether the time to progression for the DOXIL and docetaxel combination therapy group was superior to that of the group treated with docetaxel monotherapy in participants with advanced breast cancer.
This is a randomized (the study medication is assigned by a random order), active control (study medication will be compared with available standard care of treatment), parallel-group (each treatment group will be treated simultaneously at the same time and each participant only receives one treatment regimen as assigned), open-label (both the investigator and the participant know the intervention received by the participant), multicenter study designed to determine if women with locally advanced or metastatic breast cancer, who were previously treated with prior anthracycline therapy in the neoadjuvant (administration of treatment before surgery) or adjuvant setting (administration of treatment after surgery), and who also had a disease-free interval of at least 12 months since the end of their last cytotoxic therapy, would benefit from the addition of DOXIL to docetaxel therapy. Approximately 751 participants will be randomly assigned to either receive docetaxel monotherapy or DOXIL in combination with docetaxel therapy. Treatment is to continue until disease progression or the occurrence of unacceptable treatment related toxicity. Safety evaluations will include assessments of adverse events which will be recorded from the first study related procedure until 30 days after the last dose of medication; clinical laboratory tests and tests for cardiac function (multiple gated acquisition scan/echocardiogram and electrocardiogram) which will be monitored throughout the study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
LVEF (left ventricular ejection fraction)
The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
DOXIL and docetaxel combination therapy: DOXIL 30 mg/m2 solution administered by intravenous infusion, followed by docetaxel 60 mg/m2 administration by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Drug: Docetaxel · Drug: DOXIL
Docetaxel monotherapy: Docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
Drug: Docetaxel
Docetaxel monotherapy: docetaxel 75 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle. DOXIL in combination with docetaxel: docetaxel 60 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle
DOXIL 30 mg/m2 solution administered by intravenous infusion over 1 hour on Day 1 of every 21-day cycle.
Also known as: DOXIL in combination with Docataxel
Time to Progression
Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first.
Time frame: From date of randomization until date of disease progression or death, whichever occurred first, until approximately 485 events of disease progression or death were observed, as assessed approximately 15 months after the last patient was enrolled
Overall Survival
Time interval in months between the date of randomization and the participant's death from any cause.
Time frame: From the date of randomization until the participant's death from any cause, as assessed until approximately 485 death events were observed which is assessed approximately 25 months after the last patient was enrolled
Response Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR)
Number of participants in the evaluable population who achieved a CR or PR as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR: Disappearance of all target lesions and PR: at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. Response was assessed by Computed Tomography (CT)/Magnetic Resonance Imaging (MRI).
Time frame: Up to 30 to 42 days after last dose of study medication
A total of 751 participants were enrolled and randomized at 143 sites in 19 countries.
| Milestone | Docetaxel | DOXIL+Docetaxel |
|---|---|---|
| Started | 373 | 378 |
| Completed | 4 | 5 |
| Not completed | 369 | 373 |
| Withdrew: Progressive disease | 220 | 189 |
| Withdrew: Physician decision | 61 | 58 |
| Withdrew: Withdrawal by subject | 38 | 46 |
| Withdrew: Adverse event | 29 | 48 |
| Withdrew: 2cycles therapy beyond complete response | 9 | 16 |
| Withdrew: Death | 9 | 7 |
| Withdrew: Lost to follow-up | 1 | 3 |
| Withdrew: Other | 2 | 6 |
Time interval in months between the date of randomization and the participant's death from any cause.
| Months | Docetaxel | DOXIL+Docetaxel |
|---|---|---|
| Overall Survival | 20.7 (18.3 to 26.3) | 20.4 (19.0 to 23.1) |
Number of participants in the evaluable population who achieved a CR or PR as per Response Evaluation Criteria In Solid Tumors (RECIST) criteria. CR: Disappearance of all target lesions and PR: at least a 30% decrease in the sum of longest diameter (LD) of target lesions taking as reference the baseline sum LD. Response was assessed by Computed Tomography (CT)/Magnetic Resonance Imaging (MRI).
| Participants | Docetaxel | DOXIL+Docetaxel |
|---|---|---|
| Response Rate: Number of Participants in the Evaluable Population Who Achieved a Complete Response (CR) or Partial Response (PR) | 95 | 129 |
Time interval in months between the date of randomization and the date of disease progression or death due to progression, whichever occurred first.
| Months | Docetaxel | DOXIL+Docetaxel |
|---|---|---|
| Time to Progression | 7.0 (5.9 to 7.7) | 9.8 (8.1 to 10.5) |
Collected over From first dose of study medication until 30 days after the last dose of study medication.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Docetaxel | — | 59/373 (15.8%) | 340/373 (91.2%) |
| DOXIL+Docetaxel | — | 69/377 (18.3%) | 359/377 (95.2%) |
| Event | Docetaxel | DOXIL+Docetaxel |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 14/373 | 17/377 |
| PneumoniaInfections and infestations | 0/373 | 12/377 |
| Febrile neutropeniaBlood and lymphatic system disorders | 10/373 | 10/377 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 0/373 | 7/377 |
| PyrexiaGeneral disorders | 3/373 | 6/377 |
| Neutropenic sepsisInfections and infestations | 4/373 | 0/377 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 4/373 | 0/377 |
| LeukopeniaBlood and lymphatic system disorders | 1/373 | 4/377 |
| VomitingGastrointestinal disorders | 3/373 | 4/377 |
| StomatitisGastrointestinal disorders | 1/373 | 4/377 |
| Event | Docetaxel | DOXIL+Docetaxel |
|---|---|---|
| NeutropeniaBlood and lymphatic system disorders | 241/373 | 244/377 |
| Palmar-plantar erythrodysaesthesia syndromeSkin and subcutaneous tissue disorders | 5/373 | 229/377 |
| Mucositis/stomatitisGastrointestinal disorders | 53/373 | 195/377 |
| AlopeciaSkin and subcutaneous tissue disorders | 169/373 | 181/377 |
| LeukopeniaBlood and lymphatic system disorders | 99/373 | 126/377 |
| AstheniaGeneral disorders | 72/373 | 110/377 |
| NauseaGastrointestinal disorders | 80/373 | 105/377 |
| FatigueGeneral disorders | 56/373 | 78/377 |
| Peripheral neuropathyNervous system disorders | 68/373 | 78/377 |
| AnaemiaBlood and lymphatic system disorders | 62/373 | 75/377 |
| Age, Continuous(years) | Docetaxel | DOXIL+Docetaxel | Total |
|---|---|---|---|
| Mean | 52.0 ± 9.23 | 52.8 ± 9.17 | 52.4 ± 9.20 |
| Sex: Female, Male(Participants) | Docetaxel | DOXIL+Docetaxel | Total |
|---|---|---|---|
| Female | 373 | 378 | 751 |
| Male | 0 | 0 | 0 |
Showing the first 100 of 151 sites across 18 countries. Choose a country and city above to see the rest.
The record gives a start of Sep 2004, a primary completion of Dec 2008 and a completion of Dec 2008. It does not say whether these dates are actual or estimated.
Results were first posted in Oct 2012, 3 years 10 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Liposomal doxorubicin
Johnson & Johnson Pharmaceutical Research & Development, L.L.C. →